Bristol-Myers Squibb will present new data on the potential of its immunotherapy agent Opdivo (nivolumab) in combination with Yervoy (ipilimumab), and combinations with or without Opdivo of other investigational immunotherapies, to treat various cancers.
The presentations will be made at the Society for Immunotherapy of Cancer (SITC)’s 31st Annual Meeting, opening in Maryland on Wednesday and running through Nov. 13.
“We look forward to presenting new data at SITC from our innovative Immuno-Oncology pipeline,” Fouad Namouni, MD, head of development, Oncology, Bristol-Myers Squibb, said in a news release. “Research has shown that targeting multiple immune system pathways may enhance anti-tumor responses, and there are a vast number of combinations to explore.”
Among other experimental immunotherapies, the company will present data on its CD137 antibody urelumab in combination with rituximab (Rituxan) or cetuximab (Erbitux) in patients with refractory lymphoma. Urelumab is meant to bind and activate CD137-positive immune cells, stimulating a strong immune response against the tumor cells.
The abstract, “Assessing the potential for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors,” will be presented in a poster session on Friday.
Data on urelumab in combination with nivolumab in patients with hematologic and solid tumors will also feature in an oral presentation.
In addition, the company will present early data from the Phase 1/2 CheckMate 32 (NCT01928394) study assessing on the combination of nivolumab and ipilimumab in metastatic urothelial carcinoma, as well as the from another Phase 1/2 trial (NCT01714739) studying the natural killer cell-targeted antibody lirilumab in combination with nivolumab in head and neck squamous cell carcinoma.
Results from the initial administration of an inhibitor of the immune checkpoint protein LAG-3 (called BMS-986016) alone or in combination with nivolumab in patients with hematological and solid tumors will also be shown at the conference. The company also will present results showing that ipilimumab enhances vaccine-induced T-cell responses in non-human primate models.
Bristol-Myers is studying a wide range of immunotherapy combination therapies, and, by early 2017, expects to have 13 more immunotherapy compounds and seven targeted oncology compounds in the clinic.